bioAffinity advances CyPath Lung for surveillance of lung cancer survivors

bioAffinity Technologies, Inc.

Announces potential use of CyPath Lung for post-treatment surveillance; >680,000 Americans living with prior lung cancer diagnosis.
NSCLC recurrence after curative treatment runs 20-55%; ASCO recommends imaging every 6 months for 2 years.
CyPath Lung detection trial: 92% sensitivity, 87% specificity, 88% accuracy, 99% NPV; not yet validated for surveillance.
Company cites 3 years of commercial experience and case studies supporting risk stratification of challenging nodules.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.